Abstract
Solid tumors contain several different types of malignant cells. This cellular heterogeneity complicates therapy for at least two reasons. First, each subpopulation may respond differently to a given treatment. Second, cancer cells are plastic, and thus may convert from a therapy-sensitive to a therapy-resistant cell type represented by another subpopulation. Therefore, successful therapies will have to target numerous malignant cell types, not just the rapidly proliferating cells as most standard treatments do. Immunotherapies with T cells engineered to recognize cancer cells via bispecific antibodies (bsAbs) or chimeric antigen receptors (CARs) are particularly promising approaches with potential to ablate both dividing and non/slow-dividing subpopulations of cancer cells. Here, we discuss several patents associated with exceptionally effective bsAbs of the tandem single-chain variable fragment (taFv) class and untangle a part of the complex network of patents directly or indirectly related to CARs. Furthermore, we speculate on the future of bsAbs and CARs for both treatment and prevention of solid tumors such as prostate cancer.
Keywords: Antibody, BiTE, bispecific, cancer, CAR, scFv, taFv.
Recent Patents on Anti-Cancer Drug Discovery
Title:Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Volume: 8 Issue: 3
Author(s): Markus D. Lacher and Maurizio Provenzano
Affiliation:
Keywords: Antibody, BiTE, bispecific, cancer, CAR, scFv, taFv.
Abstract: Solid tumors contain several different types of malignant cells. This cellular heterogeneity complicates therapy for at least two reasons. First, each subpopulation may respond differently to a given treatment. Second, cancer cells are plastic, and thus may convert from a therapy-sensitive to a therapy-resistant cell type represented by another subpopulation. Therefore, successful therapies will have to target numerous malignant cell types, not just the rapidly proliferating cells as most standard treatments do. Immunotherapies with T cells engineered to recognize cancer cells via bispecific antibodies (bsAbs) or chimeric antigen receptors (CARs) are particularly promising approaches with potential to ablate both dividing and non/slow-dividing subpopulations of cancer cells. Here, we discuss several patents associated with exceptionally effective bsAbs of the tandem single-chain variable fragment (taFv) class and untangle a part of the complex network of patents directly or indirectly related to CARs. Furthermore, we speculate on the future of bsAbs and CARs for both treatment and prevention of solid tumors such as prostate cancer.
Export Options
About this article
Cite this article as:
Lacher D. Markus and Provenzano Maurizio, Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (3) . https://dx.doi.org/10.2174/15748928113088880003
DOI https://dx.doi.org/10.2174/15748928113088880003 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In situ Generated <sup>212</sup>Pb-PSMA Ligand in a <sup>224</sup>Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
Current Radiopharmaceuticals Synthesis, Biological Evaluation, Molecular Docking Study and Acute Oral Toxicity Study of Coupled Imidazole-Pyrimidine Derivatives
Letters in Drug Design & Discovery Therapeutic Potential of Non-Coding RNAs and TLR Signalling Pathways in Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Subject Index to Volume 9
Current Pharmaceutical Design Emerging Immunotargets and Immunotherapies in Prostate Cancer
Current Drug Targets Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Treatment of PSA only Recurrence of Prostate Cancer After Prior Local Therapy
Current Pharmaceutical Design Ghrelin and the Brain-gut Axis as a Pharmacological Target for Appetite Control
Current Pharmaceutical Design Functionalized Upconversion Nanoparticles: Versatile Nanoplatforms for Translational Research
Current Molecular Medicine Roles of Laminin-332 and α6β4 Integrin in Tumor Progression
Mini-Reviews in Medicinal Chemistry Current Status and Perspectives Regarding the Therapeutic Potential of Targeting EGFR Pathway by Curcumin in Lung Cancer
Current Pharmaceutical Design Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets Prediction of the Ebola Virus Infection Related Human Genes Using Protein-Protein Interaction Network
Combinatorial Chemistry & High Throughput Screening Synthesis and Biological Evaluation of Estradiol-Core Derivatives Bearing a Fused γ-Lactone as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Current Enzyme Inhibition Role of Nuclear Imaging in Cardiac Amyloidosis Management: Clinical Evidence and Review of Literature
Current Medical Imaging BRCA1 as Target for Breast Cancer Prevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on the Identification and Clinical Application of microRNAs and Target Genes
Recent Patents on DNA & Gene Sequences Oxidative Imbalance and Anxiety Disorders
Current Neuropharmacology The Anti-Inflammatory Role of Annexin-1 in Arthritis
Current Rheumatology Reviews